NCT02463045View on ClinicalTrials.gov

Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Ulcerative Colitis
Interventions
DRUG

TOP1288

Trial Locations (1)

Unknown

CTU, London

All Listed Sponsors
lead

Topivert Pharma Ltd

INDUSTRY

NCT02463045 - Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects | Biotech Hunter | Biotech Hunter